Resimasp. z o.o.
Other research and experimental development on natural sciences and engineering
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2020-07-29
Share capital
60 000,00 PLN
Registered address
ul. Gen. Władysława Andersa 38, 15-113 Białystok, Poland
Financials
Revenue history (in k)
Filing timeliness
1 of 5 financial statements was filed late (for 2024, 353 days late).
- 202503/07/2026
- 202403/07/2026
- 202319/06/2024
- 202222/05/2023
- 202106/07/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Authorized Representatives
Jakub Adrian Rudnicki – Management Board Member
Łukasz Głowacki – President of the Management Board
Manner of representation
Each member of the management board independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Łukasz Głowackiage 31 | 600 | $8,103.73 | 50% |
Jakub Adrian Rudnickiage 30 | 600 | $8,103.73 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-08-06.
14 1020 1332 0000 1702 1246 1093
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Faurecia R&D CenterS.A. | $33,566,047.21 | faureciardcentersa.pl | ||
| Fibro-Labsp. z o.o. | $915,089.10 | fibro-lab.pl | ||
| CTI Clinical Trial And Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | ||
| Pectore-Ecosp. z o.o. | $391,024.37 | pectore-eco.pl | ||
| Park TechnologicznyS.A. | $297,264.48 | pt.koszalin.pl | ||
| Alergo-Med Specjalistyczna Przychodnia Lekarskasp. z o.o. | $271,470.30 | alergomed.tarnow.pl | ||
| Nanoo Printerssp. z o.o. | $150,791.60 | nanooprinters.eu | ||
| Solarstopsp. z o.o. | $65,910.57 | solarstop.pl | ||
| .Protsp. z o.o. | $34,756.89 | dotprot.com | ||
| EFMS.A. | $8,156.49 | engineers4medicine.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-01-02 | Business resumed | |
| 2024-01-01 | Business suspended | |
| 2020-07-29 | Entered in the register |
FAQ
The main business activity of Resima focuses on other research and experimental development on natural sciences and engineering.
The company was registered in the Polish National Court Register (KRS) on July 29, 2020.
The headquarters is located at: ul. Gen. Władysława Andersa 38, 15-113 Białystok.
The management board consists of: Jakub Adrian Rudnicki (Member of the Management Board) and Łukasz Głowacki (President of the Management Board).
The share capital of the company is PLN 60,000 (approx. $16,207).
The latest available financial statement covers the period from January 1, 2023 to December 31, 2023.
The company reported a revenue of $6,095 in 2023, which is an increase of 33557.5% compared to 2022.
No, the company recorded a net loss of $3,192 in 2023. For comparison, in 2022 the loss was $6,385, meaning the company reduced its loss by 52.9%.
The largest operating cost category falls under other operating costs. This category amounted to $4,528 in 2023, representing 58% of all operating expenses.
Last updated: 2026-10-04